NCT05322811

Brief Summary

The purpose of the study was to examine the emotional state of the patients with neurological disorders. The evaluation was conducted with DASS-21 scale over 40 patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2021

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2022

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

February 3, 2022

Completed
2 months until next milestone

First Posted

Study publicly available on registry

April 12, 2022

Completed
Last Updated

April 12, 2022

Status Verified

April 1, 2022

Enrollment Period

2 months

First QC Date

February 3, 2022

Last Update Submit

April 7, 2022

Conditions

Emotional StressEmotional DepressionAnxietyNeurologic Disorder

Keywords

stressanxietydepressionneurologic disorders

Outcome Measures

Primary Outcomes (1)

  • Emotional state score of the patients

    The Depression, Anxiety and Stress Scale - 21 Items (DASS-21) is a set of three self-report scales designed to measure the emotional states of depression, anxiety and stress. Each of the three DASS-21 scales contains 7 items, divided into subscales with similar content. Scores on the DASS-21 will need to be multiplied by 2 to calculate the final score. Minimum score 0, maximum score 116+. The high score means a worse outcome.

    through study completion, an average of 1 year

Secondary Outcomes (3)

  • Stress frequency at the participants

    through study completion, an average of 1 year

  • Depression frequency at the participants

    through study completion, an average of 1 year

  • Anxiety frequency at the participants

    through study completion, an average of 1 year

Study Arms (1)

Participants

Adults patients with neurological disorder

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients with neurological disorders

You may qualify if:

  • patients with neurological disorders

You may not qualify if:

  • not given concent
  • Incomplete questionaire answers

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Physical therapy clinic Trevlakis Emmanouil

Thessaloniki, 54635, Greece

Location

MeSH Terms

Conditions

Stress, PsychologicalDepressionAnxiety DisordersNervous System Diseases

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehaviorMental Disorders

Study Officials

  • Alexandra-Hristara Papadopoulou

    PhD Professor of Physiotherapy at IHU, Head of the Postgraduate Programme, Pediatric Physiotherapy

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

February 3, 2022

First Posted

April 12, 2022

Study Start

December 1, 2021

Primary Completion

February 1, 2022

Study Completion

February 1, 2022

Last Updated

April 12, 2022

Record last verified: 2022-04

Data Sharing

IPD Sharing
Will not share

Locations

GR(1)